Successful treatment and management of agitated delirium, a condition presenting as mental confusion, restlessness, and agitation, often occurs in medical settings, especially in critically ill or hospitalized patients. Despite its prevalence and severity, there is currently no registered treatment specifically formulated for this condition.

Current pharmacological interventions for agitated delirium typically involve sedatives and antipsychotic medications. These interventions aim to manage symptoms such as agitation, hallucinations, and delusions. However, with no specific medication approved for agitated delirium, clinicians resort to off-label use of medications like benzodiazepines (e.g., diazepam, lorazepam, midazolam), antipsychotics (e.g., haloperidol, olanzapine), and sedatives (e.g., dexmedetomidine). These interventions come with various limitations, including variable efficacy, risk of adverse effects, and challenges in dosing and administration.

Recognizing the pressing need for innovative, safe, and effective treatments for agitated delirium, Reliis has developed a novel reformulation presented in an injectable format, known as RLS-Q2201. This formulation is designed for both intravenous (IV) and subcutaneous (SC) administration, providing versatility in treatment.